AbbVie Inc. (ABBV) FY2025 Q1 P&L / Income Statement

AbbVie Inc. (ABBV) FY2025 Q1 P&L / Income Statement

Income statement for 2025-01-01 through 2025-03-31. View: Key Product Portfolio by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net revenues

13,343,000,000 US dollars

Cost of products sold

4,002,000,000 US dollars

Gross profit (calculated)

9,341,000,000 US dollars

Operating expenses (calculated)

5,608,000,000 US dollars

Operating earnings

3,733,000,000 US dollars

Other income (expense), net (calculated)

negative 2,072,000,000 US dollars

Earnings before income tax expense

1,661,000,000 US dollars

Income tax expense

372,000,000 US dollars

Net earnings

1,289,000,000 US dollars

Aesthetics - Botox Cosmetic

556,000,000 US dollars

Aesthetics - Juvederm Collection

231,000,000 US dollars

Aesthetics - Other Aesthetics

315,000,000 US dollars

Eye Care - Alphagan/Combigan

60,000,000 US dollars

Eye Care - Lumigan/Ganfort

106,000,000 US dollars

Eye Care - Other Eye Care

217,000,000 US dollars

Eye Care - Ozurdex

123,000,000 US dollars

Oncology - Elahere

179,000,000 US dollars

Oncology - Epkinly

51,000,000 US dollars

Oncology - Imbruvica

738,000,000 US dollars

Oncology - Venclexta

665,000,000 US dollars

Immunology - Humira

1,121,000,000 US dollars

Immunology - Rinvoq

1,718,000,000 US dollars

Immunology - Skyrizi

3,425,000,000 US dollars

Neuroscience - Botox Therapeutic

866,000,000 US dollars

Neuroscience - Duodopa

96,000,000 US dollars

Neuroscience - Other Neuroscience

59,000,000 US dollars

Neuroscience - Qulipta

193,000,000 US dollars

Neuroscience - Ubrelvy

240,000,000 US dollars

Neuroscience - Vraylar

765,000,000 US dollars

Neuroscience - Vyalev

63,000,000 US dollars

Other Key Products - Linzess/Constella

148,000,000 US dollars

Other Key Products - Mavyret

306,000,000 US dollars

Undisclosed (calculated)

1,102,000,000 US dollars

Acquired IPR&D and milestones

248,000,000 US dollars

Research and development

2,067,000,000 US dollars

Selling, general and administrative

3,293,000,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Of which attributable to AbbVie Inc.: $1.29 B; to noncontrolling interests: $3.00 M.